United StatesHouse Bill 3493HR 3493

Global Fairness in Drug Pricing Act

Health

4 pages

house
senate
president

Introduced May 19, 2025 by Ro Khanna · Last progress May 19, 2025

House Votes

Pending Committee

May 19, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Senate Votes

Vote Data Not Available

Presidential Signature

Signature Data Not Available

Recorded Votes

Recorded roll calls only

0 recorded

No recorded votes yet

What do you think?

Sponsors (8)

AI Summary

Text Versions

Introduced in House

May 19, 2025•4 pages

View PDF

Amendments

No Amendments

Directs federal officials to take several steps to lower U.S. prescription drug prices and to study drug manufacturer practices. It requires a rulemaking plan to set most-favored-nation (MFN) price targets, allows individual importation waivers when an imported drug is certified safe and cheaper, pushes antitrust enforcement against anti-competitive manufacturer conduct, encourages direct-to-consumer purchase programs, and orders a study of manufacturer behaviors that may raise prices or restrict access.